Microviable Therapeutics develops microbiota ecosystem products and microbiome therapies to improve human health.
Microviable Therapeutics has raised $1.6M in total funding. The most recent round was Seed. The last funding was announced in April 2022.
Microviable Therapeutics's investors include Immunomet Intolerance and Dysbiosis.
Microviable Therapeutics is headquartered in Gijón, Spain.
Microviable Therapeutics develops microbiota ecosystem products and microbiome therapies to improve human health.
Microviable Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Microviable Therapeutics — Funding & Investors." VCBacked, April 19, 2022, https://www.vcbacked.co/company/microviable-therapeutics. Accessed August 17, 2026.
VCBacked. (2022). Microviable Therapeutics — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/microviable-therapeutics
{{cite web |title=Microviable Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/microviable-therapeutics |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated